ENTRADA THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $1M | ↓-96.5% | — | — | — |
| 2025-09-30 | $2M | ↓-91.8% | $-44M | ↓-214.5% | -2915.2% |
| 2025-06-30 | $2M | ↓-97.9% | $-43M | ↓-178.3% | -2402.5% |
| 2025-03-31 | $21M | ↓-65.2% | $-17M | ↓-173.8% | -106.0% |
| 2024-12-31 | $37M | ↓-10.6% | $1M | — | — |
| 2024-09-30 | $20M | ↓-55.3% | $-14M | ↓-139.6% | -110.7% |
| 2024-06-30 | $95M | ↑+421.2% | $55M | ↑+312.2% | 56.4% |
| 2024-03-31 | $59M | ↑+134.0% | $23M | ↑+452.1% | 35.7% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$1M
↓-96.5% -$36M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
TRDA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyTRDA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics